Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardioprotective-Nephroprotective Effects of Sevoflurane vs Propofol in Double Valve Surgery
2025-520812-33-00Phase 3Authorised
- Sponsor
- Fundación IMABIS
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sevoflurane in Cardiac valve disease (VHD), Myocardial injury and acute kidney failure (AKF) (2 arms), sponsored by Fundación IMABIS. Primary endpoints: Cardiac index, Creatinine and 12 more. Planned start Jan 2025; status: authorised.
02
Drugs
sevoflurane
03
Conditions
Cardiac valve disease (VHD)Myocardial injuryacute kidney failure (AKF)
Beyond the preview
Go deeper on 2025-520812-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520812-33-00.